En studie for å lære mer om hvor trygg BAY 3771249 er og hvor godt den virker hos personer med avansert eller metastatisk tykktarmskreft som har en KRAS G12D-mutasjon
Hovedprotokoll: En åpen studie for å evaluere sikkerhet, tolerabilitet, farmakokinetikk, farmakodynamikk og effekt av BAY 3771249 som monoterapi eller i kombinasjon med andre kreftbehandlinger hos deltakere med solide svulster som har en KRAS G12D-mutasjon Delforsøksprotokoll: En åpen, flerkohortstudie for å evaluere sikkerhet, tolerabilitet, farmakokinetikk, farmakodynamikk og foreløpig antikreftaktivitet av BAY 3771249 som monoterapi og i kombinasjon med cetuximab hos deltakere med avansert/metastatisk kolorektal adenokarsinom som har en KRAS G12D-mutasjon
Researchers are looking for a better way to treat people who have advanced or metastatic colorectal cancer (CRC) with a specific mutation, the G12D mutation, in a protein called KRAS.
Colorectal cancer (CRC) is a common type of cancer that affects the large bowel (colon) or the rectum (the section at the end of the bowel). When CRC spreads to other parts of the body, it is called advanced or metastatic CRC. Some people with CRC have the G12D mutation in the KRAS protein. This mutation is linked to a poorer outlook and fewer treatment options. Currently, there are no approved treatments that specifically target this mutation.
KRAS is a protein that helps control how cells grow and divide. When it is mutated, it can cause cells to grow uncontrollably, leading to cancer. The study drug, BAY 3771249, is designed to block the activity of KRAS with G12D mutation, which may help slow or stop the growth of cancer cells. BAY 3771249 can be given alone or together with another drug called cetuximab.
The main purpose of this study is to learn how safe BAY 3771249 is, how well people tolerate it, how the body processes the drug, and whether it can help shrink or control tumors in people with advanced or metastatic CRC that has the KRAS G12D mutation. The study will also look at how BAY 3771249 works when given alone or with cetuximab, especially in people who have already tried other treatments for their cancer.
Researchers will measure, among others:
The number and seriousness of health problems (adverse events) after receiving BAY 3771249.
The number of participants who experience a dose-limiting side effect (DLT) at each dose level.
The number of participants whose tumors shrink or disappear (overall response rate, ORR) as measured by standard criteria.
How much of the drug is in the blood over time (AUC) and the highest amount in the blood (Cmax).
Some participants will receive BAY 3771249 alone (monotherapy), and others will receive BAY 3771249 with cetuximab (combination therapy).
The study will start with lower doses and gradually increase to find the highest safe dose (dosage escalation). After the safe dose is found, more participants may join the study to receive it (dosage expansion). In some parts of the study, participants may be randomly assigned to different groups or doses. The study is open-label, meaning both participants and doctors know which treatment is being given.
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, even if they do not think it is related to the study treatment.
The study doctors and their team will contact participants to learn about their health until they complete the study.
If a participant benefits from the treatment, it might be possible to continue receiving BAY 3771249 after the end of the study. The findings from this study may help develop a new treatment option for people with advanced or metastatic CRC with a KRAS G12D mutation.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Bayer Clinical Trials Contact
- Telefonnummer: 18888422937
- E-post: clinical-trials-contact@bayer.com
Studiesteder
-
-
New South Wales
-
Albury, New South Wales, Australia, 2640
- Har ikke rekruttert ennå
- Border Medical oncology - Albury Wodonga Regional Cancer Centre
-
Waratah, New South Wales, Australia, 2298
- Rekruttering
- Calvary Mater Hospital Newcastle - Oncology
-
-
Victoria
-
Malvern, Victoria, Australia, 3144
- Har ikke rekruttert ennå
- Cabrini Health Oncology Research
-
-
-
-
East Flanders
-
Ghent, East Flanders, Belgia, 9000
- Har ikke rekruttert ennå
- Ghent University Hospital | Drug Research Unit Department
-
-
-
-
Capital Region / Region Hovedstaden
-
Copenhagen, Capital Region / Region Hovedstaden, Danmark, 2100
- Har ikke rekruttert ennå
- Rigshospitalet Copenhagen University Hospital | Oncology Department
-
-
Region of Southern Denmark / Region Syddanmark
-
Odense, Region of Southern Denmark / Region Syddanmark, Danmark, 5000
- Har ikke rekruttert ennå
- Odense University Hospital | Svendborg Sygehus - Oncology Department
-
-
-
-
Uusimaa
-
Helsinki, Uusimaa, Finland, 00029
- Har ikke rekruttert ennå
- HUS-Yhtymä, Helsingin yliopistollinen sairaala (HUS) - Syöpäkeskus
-
-
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85054
- Har ikke rekruttert ennå
- Mayo Clinic - Cancer Center - Phoenix
-
-
California
-
Duarte, California, Forente stater, 91010
- Rekruttering
- City of Hope - Duarte Cancer Center
-
San Diego, California, Forente stater, 92037
- Har ikke rekruttert ennå
- UC San Diego Health - Moores Cancer Center
-
-
Colorado
-
Denver, Colorado, Forente stater, 80218
- Tilbaketrukket
- Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's
-
-
New York
-
New York, New York, Forente stater, 10029
- Har ikke rekruttert ennå
- Icahn School of Medicine at Mount Sinai - Oncology
-
-
Texas
-
Irving, Texas, Forente stater, 75039
- Rekruttering
- NEXT Dallas - Oncology Department
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- START | San Antonio
-
-
-
-
-
Roma, Italia, 00128
- Har ikke rekruttert ennå
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I
-
-
-
-
North Holland
-
Amsterdam, North Holland, Nederland, 1066 CX
- Har ikke rekruttert ennå
- Nederlands Kanker Instituut
-
-
-
-
-
Singapore, Singapore, 119074
- Rekruttering
- National University Hospital Medical Centre
-
Singapore, Singapore, 168583
- Rekruttering
- National Cancer Center Singapore - Oncology Department
-
-
-
-
Barcelona
-
Barcelona, Barcelona, Spania, 08035
- Har ikke rekruttert ennå
- Hospital Universitari Vall D Hebron | Oncologia
-
-
Madrid
-
Madrid, Madrid, Spania, 28050
- Har ikke rekruttert ennå
- Hospital Universitario Hm Sanchinarro | Oncologia
-
-
-
-
Stockholm County
-
Stockholm, Stockholm County, Sverige, 171 76
- Har ikke rekruttert ennå
- Karolinska Universitetssjukhuset - Solna - Fas I-enheten Solna CKC
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- KRAS G12D mutated solid tumor
- Participant must be ≥18 years old or the legal age of consent in the jurisdiction in which the study is taking place when signing the screening ICF
- At least one measurable lesion as per RECIST v1.1. outside the CNS
- Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1
- Male or Female: Contraceptive use by participant or participant's partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Life expectancy of at least 3 months in the opinion of the Investigator
- Histologically/pathologically documented diagnosis of advanced/metastatic adenocarcinoma of the colon and rectum.
- Adequate hematologic and end-organ function
Exclusion Criteria:
- Leptomeningeal disease or carcinomatous meningiti
- Uncontrolled and/or active/symptomatic brain metastases.
- Significant traumatic injury or major surgical procedure within 4 weeks of first dose of study intervention
- Known hypersensitivity to any component of study intervention
- Previous (within 3 years) or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in the respective substudy.
- Active infection requiring systemic anti-infective therapy within 14 days of first dose of study intervention
- Known HIV infection
- Active Hepatitis B virus (HBV) infection
- Active Hepatitis C virus (HCV) infection
- Significant cardiac disorder
- History of risk factors for torsade de pointes (TdP) (e.g., heart failure, family history of long QT syndrome)
- Participants with inadequately managed diabetes as assessed by the Investigator
- Toxicities from prior anticancer therapy, defined as not having resolved to Grade ≤1 or as specified in the respective substudy protocol as per NCI CTCAE v.6.0 with the following exceptions: Alopecia of any grade, Peripheral neuropathy Grade ≤2, Autoimmune endocrine disorders Grade ≤2 managed with stable endocrine replacement therapy
- History of (non-infectious) pneumonitis/interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis (unless it has resolved without sequelae without use of steroids), or any evidence of clinically-active pneumonitis/ILD
- History of the following eye disorders: keratitis, ulcerative keratitis
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Dosage escalation
In the dosage escalation part, different dose levels of BAY 3771249 administered as monotherapy and in combination with cetuximab are planned. |
Oral Intravenous (IV) infusion |
|
Eksperimentell: Dosage expansion
In the dosage expansion part, participants will receive BAY 3771249 either as monotherapy or in combination with cetuximab until disease progression as defined by RECIST v1.1, the occurrence of unacceptable toxicity, or the fulfillment of any other withdrawal criteria. |
Oral Intravenous (IV) infusion |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in laboratory test results
Tidsramme: Up to approximately 2 years
|
Hematology, serum chemistry, urinalysis and coagulation tests. Applicable in Dosage escalation and expansion |
Up to approximately 2 years
|
|
Change from baseline in vital signs: Blood pressure
Tidsramme: Up to approximately 2 years
|
Applicable in Dosage escalation and expansion |
Up to approximately 2 years
|
|
Change from baseline in vital signs: Body temperature
Tidsramme: Up to approximately 2 years
|
Applicable in Dosage escalation and expansion |
Up to approximately 2 years
|
|
Change from baseline in vital signs: Oxygen saturation
Tidsramme: Up to approximately 2 years
|
Applicable in Dosage escalation and expansion |
Up to approximately 2 years
|
|
Change from baseline in vital signs: Pulse rate
Tidsramme: Up to approximately 2 years
|
Applicable in Dosage escalation and expansion |
Up to approximately 2 years
|
|
Change from baseline in vital signs: Respiratory rate
Tidsramme: Up to approximately 2 years
|
Applicable in Dosage escalation and expansion |
Up to approximately 2 years
|
|
Number of participants experiencing a dose-limiting toxicity (DLT) at each dosage
Tidsramme: Up to approximately 3 weeks
|
Applicable in Dose escalation part |
Up to approximately 3 weeks
|
|
Number of participants with Treatment-emergent adverse events (TEAEs)
Tidsramme: Up to approximately 2 years.
|
Applicable in Dosage escalation and expansion |
Up to approximately 2 years.
|
|
Objective response rate (ORR) as determined by the Investigator according to RECIST v1.1
Tidsramme: Up to approximately 2 years
|
Applicable in Dosage escalation and expansion |
Up to approximately 2 years
|
|
Severity of TEAEs
Tidsramme: Up to approximately 2 years.
|
Applicable in Dosage escalation and expansion |
Up to approximately 2 years.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pharmacokinetics (PK) parameters such as area under the concentration vs time curve (AUC)
Tidsramme: Up to approximately 2 years
|
Applicable in Dosage escalation |
Up to approximately 2 years
|
|
PK parameters such as maximum observed drug concentration (Cmax)
Tidsramme: Up to approximately 2 years
|
Applicable in Dosage escalation |
Up to approximately 2 years
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 23111-1
- 2025 (U.S. NIH-stipend/kontrakt)
- 2025-523648-11-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .